CAPITAL IMPROVEMENT PROGRAM (PROJECT WAFER)
Genentech is a leading biotechnology company that has delivered on the promise of biotechnology for over 30 years by discovering, developing, manufacturing and commercializing various medicines to treat patients with serious or life-threatening medical conditions. Genentech was founded in 1976, and is considered to be the founder of the biotechnology industry. Genentech became a member of the Roche Group in March of 2009 and has its headquarters in South San Francisco, California.
The company’s South San Francisco site has grown to 48 buildings and serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech is currently pursuing a very aggressive expansion program to substantially increase their capacity and R&D facilities. EPC is currently assisting Genentech with the program management support of their capital program.
EPC is currently working with Genentech's Capital Projects Group as an architectural lead on Project WAFER. This $19 million project will add approximately 90,000 square-feet of office and warehouse space to Buildings 3 and 4 at Genentech's Vacaville manufacturing facility. The Building 3 portion of Project WAFER will increase the size of the active GMP warehouse by 40,000 square-feet. The new structure is a two-story tilt-up concrete panel addition and includes 40-foot high rack storage units, a new materials receiving/sampling area, a hazardous materials storage/sampling area, locker rooms and an office area. The Building 4 portion of Project WAFER will provide 50,000 square-feet of office space for engineering and facilities personnel. This addition is a two-story tilt-up concrete panel structure and will include a new computer room, a drawing archive area, conference space, open offices, locker rooms, a calibration lab and a facilities maintenance shop.